Unlock stock picks and a broker-level newsfeed that powers Wall Street.

LSE - Delayed Quote USD

(0ADR.L)

244.92
-24.59
(-9.12%)
As of March 14 at 1:34:29 PM GMT. Market Open.
Loading Chart for 0ADR.L
  • Previous Close 269.51
  • Open 247.50
  • Bid --
  • Ask --
  • Day's Range 244.92 - 247.50
  • 52 Week Range 244.92 - 247.50
  • Volume 12,240
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.30
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date May 8, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

www.insulet.com

3,900

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: 0ADR.L

View More

Compare To: 0ADR.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0ADR.L

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    20.19%

  • Return on Assets (ttm)

    6.80%

  • Return on Equity (ttm)

    43.03%

  • Revenue (ttm)

    2.07B

  • Net Income Avi to Common (ttm)

    418.3M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    953.4M

  • Total Debt/Equity (mrq)

    118.37%

  • Levered Free Cash Flow (ttm)

    155.28M

Research Analysis: 0ADR.L

View More

Company Insights: 0ADR.L

Research Reports: 0ADR.L

View More
Waiting for permission
Allow microphone access to enable voice search

Try again.